PACB logo

PACB

Pacific Biosciences of California, Inc.NASDAQHealthcare
$1.34-0.74%ClosedMarket Cap: $404.7M

As of 2026-04-06

Valuation

View Details

P/E (TTM)

PEG

P/B

75.63

P/S

2.53

EV/EBITDA

-6.87

DCF Value

$-11.00

FCF Yield

-30.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

28.2%

Operating Margin

-346.1%

Net Margin

-341.5%

ROE

-1123.3%

ROA

-121.1%

ROIC

-75.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$44.6M$-40.4M$-0.13
FY 2025$160.0M$-546.4M$-1.82
Q3 2025$38.4M$-38.0M$-0.13
Q2 2025$39.8M$-41.9M$-0.14

Analyst Ratings

View All
BarclaysUnderweight
2026-03-06
BarclaysEqual Weight
2025-12-15
Piper SandlerNeutral
2025-11-11
Stephens & Co.Overweight
2025-11-10
Piper SandlerNeutral
2025-08-11

Trading Activity

Insider Trades

View All
Gibson James R IIofficer: See Remarks
SellFri Apr 03
Gibson Christopherdirector
SellThu Mar 05
Gibson Christopherdirector:
SellThu Mar 05
Gibson Christopherdirector
SellThu Mar 05
Farmer Micheleofficer: See Remarks
SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NASDAQ

Beta

2.33

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Peers